SCHEMBL18359609

SCHEMBL18359609

O=c1[nH]c(=O)c2cncn2[nH]1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
GDA Q9Y2T3 1/20 0.31
DAO P14920 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269078 0.65 CHEK1 (0.48) TNKSTNKS2DAO
SCHEMBL18414640 0.63 TP53 (0.33)
SCHEMBL12102064 0.62 TNKS2 (0.36) TNKSTNKS2
SCHEMBL15408051 0.60 PDE3B (0.42) TNKS
SCHEMBL17611146 0.58 PDE9A (0.45) GDA
SCHEMBL18430179 0.58 DPYD (0.35)
SCHEMBL16007189 0.55 TYMP (0.31) GDA
SCHEMBL18232359 0.54 GDA (0.33) GDA
SCHEMBL4951195 0.49
SCHEMBL1821183 0.48 PDE3B (0.33) GDA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117362318-A PB2 inhibitor and preparation method and application thereof 西藏海思科制药有限公司 2024-01-09 CN disclosed
CN-115698011-B PB2 inhibitor and preparation method and application thereof 四川海思科制药有限公司 2023-10-20 CN disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 US disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 US disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 US disclosed
EP-4180434-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 EP disclosed
EP-4180434-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 EP disclosed
CN-115698011-A PB2 inhibitor and preparation method and application thereof 四川海思科制药有限公司 2023-02-03 CN disclosed
WO-2017004134-A1 IRAK INHIBITORS AND USES THEREOF NIMBUS IRIS, INC. (US) 2017-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP11B2, WEE2, CYP11B1 TNKS 4219/4885TNKS2 3954/4885GDA 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.